Affinage

ARCN1

Coatomer subunit delta · UniProt P48444

Length
511 aa
Mass
57.2 kDa
Annotated
2026-06-09
100 papers in source corpus 2 papers cited in narrative 2 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 3/3 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ARCN1 encodes the delta subunit of the COPI coatomer complex, which mediates intracellular protein transport between the endoplasmic reticulum and the Golgi apparatus (PMID:27476655). Loss-of-function heterozygous mutations in ARCN1 impair type I collagen transport and reduce collagen secretion, triggering ER stress and underlying a craniofacial/skeletal syndrome characterized by micrognathia, rhizomelic shortening, and microcephalic dwarfism (PMID:27476655). Independently, ARCN1 acts as a pro-viral host factor required for efficient influenza A virus internalization; its expression is suppressed by miR-33a through targeting of the ARCN1 3' UTR, and this suppression restricts viral replication (PMID:26498766). Beyond these two functions, no further mechanistic detail has been characterized in the available corpus.

Mechanistic history

Synthesis pass · year-by-year structured walk · 2 steps
  1. 2015 Medium

    Whether ARCN1 contributes to influenza A virus infection was unknown; this work established it as a pro-viral host factor whose suppression by a host miRNA limits viral entry.

    Evidence Luciferase 3' UTR reporter assay, siRNA knockdown, and ectopic ARCN1 overexpression rescue in 293T and HeLa cells

    PMID:26498766

    Open questions at the time
    • The molecular step in internalization that requires ARCN1 is not defined
    • Whether ARCN1's COPI function is mechanistically involved in viral entry was not tested
    • No direct interaction between ARCN1 and viral components was demonstrated
  2. 2016 Medium

    The cellular consequence of ARCN1 loss-of-function in human disease was unresolved; patient-derived cells linked heterozygous mutations to impaired collagen secretion and ER stress, providing the basis for the skeletal/craniofacial syndrome.

    Evidence ER stress assays and collagen secretion assays in ARCN1 mutant patient-derived cell lines; loss-of-function mutation analysis in a human genetics cohort

    PMID:27476655

    Open questions at the time
    • No in vitro reconstitution or structural validation of the delta-COP role was performed
    • Whether all secretory cargo or specifically collagen is affected was not delineated
    • The molecular basis for the tissue-specific (skeletal/craniofacial) phenotype is unexplained

Open questions

Synthesis pass · forward-looking unresolved questions
  • How ARCN1's role in COPI-mediated ER-Golgi transport mechanistically connects to its requirement during influenza A internalization remains unresolved.
  • No structural model of ARCN1 within the COPI coatomer in the available corpus
  • No defined direct binding partners or substrates beyond inferred collagen cargo
  • Unclear whether the viral and secretory functions share a common molecular mechanism

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Localization
GO:0005783 endoplasmic reticulum 1 GO:0005794 Golgi apparatus 1
Pathway
R-HSA-5653656 Vesicle-mediated transport 1
Complex memberships
COPI coatomer complex

Evidence

Reading pass · 2 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2016 ARCN1 encodes the delta subunit of the COPI coatomer complex, which is responsible for intracellular protein transport between the endoplasmic reticulum and the Golgi apparatus. Loss-of-function heterozygous mutations in ARCN1 cause defective type I collagen transport and reduced collagen secretion, leading to ER stress. This was established in ARCN1 mutant patient-derived cell lines showing ER stress markers and reduced collagen secretion, providing the mechanistic basis for the skeletal phenotype (micrognathia, rhizomelic shortening, microcephalic dwarfism) of the associated craniofacial syndrome. Patient-derived mutant cell line analysis (ER stress assays, collagen secretion assays); loss-of-function mutation analysis in human genetics cohort American Journal of Human Genetics Medium 27476655
2015 ARCN1 is required for efficient influenza A virus replication. miR-33a suppresses ARCN1 protein expression by targeting its 3' UTR, and knockdown of ARCN1 phenocopies miR-33a overexpression by impeding virus replication at the stage of virus internalization. Ectopic expression of ARCN1 partially rescues the inhibitory effect of miR-33a on virus replication, establishing ARCN1 as a pro-viral host factor whose suppression by miR-33a restricts influenza A infection. Luciferase reporter assay (ARCN1 3' UTR), immunoblotting, siRNA knockdown of ARCN1, ectopic ARCN1 overexpression rescue experiment, miRNA overexpression in cell lines (293T, HeLa) The Journal of General Virology Medium 26498766

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2009 Systemic manifestations and comorbidities of COPD. The European respiratory journal 1194 19407051
2006 Mortality in COPD: Role of comorbidities. The European respiratory journal 766 17138679
2020 Oxidative stress-based therapeutics in COPD. Redox biology 366 32336666
2015 The relationship between COPD and lung cancer. Lung cancer (Amsterdam, Netherlands) 329 26363803
2000 Oxidants/antioxidants and COPD. Chest 283 10843965
2019 Benralizumab for the Prevention of COPD Exacerbations. The New England journal of medicine 271 31112385
2004 Alveolar macrophages as orchestrators of COPD. COPD 244 16997739
2009 Role of HDAC2 in the pathophysiology of COPD. Annual review of physiology 243 18817512
2008 Obesity and the lung: 5. Obesity and COPD. Thorax 231 19020276
2020 COVID-19 and COPD. The European respiratory journal 216 32817205
2008 Pulmonary vascular involvement in COPD. Chest 200 18842913
2002 Systemic effects in COPD. Chest 195 12010840
2018 PRKN-regulated mitophagy and cellular senescence during COPD pathogenesis. Autophagy 192 30290714
2016 Senescence in COPD and Its Comorbidities. Annual review of physiology 190 27959617
2011 Systemic manifestations of COPD. Chest 161 21208876
2006 COPD exacerbations . 3: Pathophysiology. Thorax 161 16565268
2013 Pathophysiology of muscle dysfunction in COPD. Journal of applied physiology (Bethesda, Md. : 1985) 159 23519228
2015 COPD: balancing oxidants and antioxidants. International journal of chronic obstructive pulmonary disease 147 25673984
2019 Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. Journal of thoracic disease 137 31737343
2016 COPD and the microbiome. Respirology (Carlton, Vic.) 124 26852737
2014 Cytokine inhibition in the treatment of COPD. International journal of chronic obstructive pulmonary disease 124 24812504
2014 Clinical issues of mucus accumulation in COPD. International journal of chronic obstructive pulmonary disease 117 24493923
2022 Pathological Mechanism and Targeted Drugs of COPD. International journal of chronic obstructive pulmonary disease 116 35855746
2019 Women and COPD: do we need more evidence? European respiratory review : an official journal of the European Respiratory Society 112 30814138
2006 Reduced histone deacetylase in COPD: clinical implications. Chest 111 16424426
2013 Differences in plasma and sputum biomarkers between COPD and COPD-asthma overlap. The European respiratory journal 108 23794464
2019 Nutritional support in chronic obstructive pulmonary disease (COPD): an evidence update. Journal of thoracic disease 100 31737350
2004 Genetics of COPD. Chest 99 15136409
2012 Antioxidant pharmacological therapies for COPD. Current opinion in pharmacology 95 22349417
2018 PINK1-PARK2-mediated mitophagy in COPD and IPF pathogeneses. Inflammation and regeneration 94 30386443
2021 Natural history and mechanisms of COPD. Respirology (Carlton, Vic.) 93 33506971
2008 COPD: a pediatric disease. COPD 93 18259975
2006 Emerging role of MAP kinase pathways as therapeutic targets in COPD. International journal of chronic obstructive pulmonary disease 89 18046891
2019 Chemokines in COPD: From Implication to Therapeutic Use. International journal of molecular sciences 84 31174392
2008 Emerging pharmacotherapies for COPD. Chest 84 19059958
2002 Cytokines and therapy in COPD: a promising combination? Chest 74 12010854
2014 Management and prevention of exacerbations of COPD. BMJ (Clinical research ed.) 71 25245156
2002 Airways inflammation and COPD: epithelial-neutrophil interactions. Chest 70 12010843
2006 Antioxidant therapeutic targets in COPD. Current drug targets 68 16787173
2018 Mitochondrial Quality Control in COPD and IPF. Cells 67 30042371
2009 Associations between statins and COPD: a systematic review. BMC pulmonary medicine 67 19594891
2002 Few smokers develop COPD. Why? Respiratory medicine 67 12195843
2018 Chronic obstructive pulmonary disease (COPD) and lung cancer screening. Translational lung cancer research 66 30050772
2016 ARCN1 Mutations Cause a Recognizable Craniofacial Syndrome Due to COPI-Mediated Transport Defects. American journal of human genetics 64 27476655
2023 How inhaled corticosteroids target inflammation in COPD. European respiratory review : an official journal of the European Respiratory Society 62 37852657
2005 Murine models of COPD. Pulmonary pharmacology & therapeutics 60 16084119
2021 Oxidative Stress Promotes Corticosteroid Insensitivity in Asthma and COPD. Antioxidants (Basel, Switzerland) 59 34572965
2020 Extracellular matrix remodelling in COPD. European respiratory review : an official journal of the European Respiratory Society 59 33208482
2017 Epithelial and endothelial cell plasticity in chronic obstructive pulmonary disease (COPD). Respiratory investigation 59 28274525
2016 The inflammasome pathway in stable COPD and acute exacerbations. ERJ open research 59 27730204
2014 Structural alterations of skeletal muscle in copd. Frontiers in physiology 58 24678302
2011 COPD/emphysema: The vascular story. Pulmonary circulation 57 22140621
2006 Antioxidant therapies in COPD. International journal of chronic obstructive pulmonary disease 56 18046899
2021 Protein Biomarkers for COPD Outcomes. Chest 53 33434499
2010 Lasers, stem cells, and COPD. Journal of translational medicine 53 20158898
2018 Autophagy, selective autophagy, and necroptosis in COPD. International journal of chronic obstructive pulmonary disease 52 30349225
2000 Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 52 11057087
2017 Decreased Serum Sirtuin-1 in COPD. Chest 51 28506610
2009 Endocrinological derangements in COPD. The European respiratory journal 51 19797671
2021 Spanish COPD Guidelines (GesEPOC) 2021 Update Diagnosis and Treatment of COPD Exacerbation Syndrome. Archivos de bronconeumologia 48 34172340
2020 Senotherapy: A New Horizon for COPD Therapy. Chest 48 32057805
2008 Pulmonary hypertension associated with COPD. International journal of chronic obstructive pulmonary disease 48 18488429
2022 Mechanisms Linking COPD to Type 1 and 2 Diabetes Mellitus: Is There a Relationship between Diabetes and COPD? Medicina (Kaunas, Lithuania) 47 36013497
2015 Association between HMGB1 and COPD: A Systematic Review. Mediators of inflammation 46 26798204
2021 Towards Personalized Management of Sarcopenia in COPD. International journal of chronic obstructive pulmonary disease 45 33442246
2014 Targeting mucus hypersecretion: new therapeutic opportunities for COPD? Drugs 45 24890395
2005 Selectin antagonists : therapeutic potential in asthma and COPD. Treatments in respiratory medicine 45 15813660
2019 Extracellular vesicles in chronic obstructive pulmonary disease (COPD). Journal of thoracic disease 44 31737342
2012 Epigenetics in asthma and COPD. Biochimie 44 22874820
2006 Akt in the pathogenesis of COPD. International journal of chronic obstructive pulmonary disease 44 18046900
2022 New drugs under development for COPD. Minerva medica 43 35142480
2020 Lung epithelium damage in COPD - An unstoppable pathological event? Cellular signalling 42 31953012
2020 Sputum microbiome profiling in COPD: beyond singular pathogen detection. Thorax 42 31996401
2019 Targeting HDAC Complexes in Asthma and COPD. Epigenomes 42 34968229
2014 Epigenetic mechanisms in COPD: implications for pathogenesis and drug discovery. Expert opinion on drug discovery 42 24850530
2017 Macrophage phagocytosis cracking the defect code in COPD. Biomedical journal 39 29433833
2015 Molecular pathogenesis of cigarette smoking-induced stable COPD. Annals of the New York Academy of Sciences 38 25639503
2017 Emerging pharmaceutical therapies for COPD. International journal of chronic obstructive pulmonary disease 37 28790817
2010 Atrophy and hypertrophy signalling of the quadriceps and diaphragm in COPD. Thorax 37 20965933
2020 Epigenetic Modifications and Therapy in Chronic Obstructive Pulmonary Disease (COPD): An Update Review. COPD 36 32558592
2019 Targeting IL-5 in COPD. International journal of chronic obstructive pulmonary disease 36 31190789
2008 Translating the COPD transcriptome: insights into pathogenesis and tools for clinical management. Proceedings of the American Thoracic Society 36 19017738
2011 Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Current drug targets 35 21194405
2022 COPD lung studies of Nrf2 expression and the effects of Nrf2 activators. Inflammopharmacology 34 35441963
2011 Mast cells and COPD. Pulmonary pharmacology & therapeutics 34 21463700
2011 Genetics of COPD. Allergology international : official journal of the Japanese Society of Allergology 33 21778810
2022 Metabolomics of asthma, COPD, and asthma-COPD overlap: an overview. Critical reviews in clinical laboratory sciences 32 36420874
2015 MicroRNA-33a disturbs influenza A virus replication by targeting ARCN1 and inhibiting viral ribonucleoprotein activity. The Journal of general virology 32 26498766
2019 Sphingolipids in COPD. European respiratory review : an official journal of the European Respiratory Society 31 31694841
2013 Development of new drugs for COPD. Current medicinal chemistry 31 22963554
2011 Toll-like receptor expression in smokers with and without COPD. Respiratory medicine 31 21439805
2018 The DNA repair transcriptome in severe COPD. The European respiratory journal 29 30190272
2015 Candidate genes for COPD: current evidence and research. International journal of chronic obstructive pulmonary disease 29 26527870
2014 Sputum ADAM8 expression is increased in severe asthma and COPD. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 29 24147597
2007 A review of etiologies of depression in COPD. International journal of chronic obstructive pulmonary disease 29 18268923
2013 Metabolic derangements in COPD muscle dysfunction. Journal of applied physiology (Bethesda, Md. : 1985) 28 23288549
2020 RAGE and TLR4 differentially regulate airway hyperresponsiveness: Implications for COPD. Allergy 27 32799375
2015 Prostanoids in Asthma and COPD: Actions, Dysregulation, and Therapeutic Opportunities. Chest 27 26204554
2023 Extracellular vesicles and COPD: foe or friend? Journal of nanobiotechnology 26 37147634
2022 Extracellular vesicles and chronic obstructive pulmonary disease (COPD): a systematic review. Respiratory research 25 35382831

Missed literature

Know a paper Affinage missed for ARCN1? Flag it for the maintainers and the community.

No submissions yet.